ARTICLE | Emerging Company Profile
Elpiscience builds out global pipeline with CD39 focus
Dual-track strategy includes in-licensing for China market, but focus is on driving wholly-owned pipeline in U.S.
October 21, 2021 7:28 PM UTC
Elpiscience is taking a dual-track strategy of in-licensing molecules for the China market while prioritizing the development of a broad immuno-oncology pipeline that is headlined by a CD39 franchise.
Like many other Chinese biotechs before them, Elpiscience Biopharma Inc. launched in 2017 with a business model partly focused on licensing innovative molecules from Western companies to develop and commercialize in Greater China. ...